1. Italy Stocks

  2. •

    Healthcare

  3. •

    Medical - Devices
Otofarma S.p.A.

Otofarma S.p.A.

OTO.MI
Otofarma S.p.A.IT flagItalian Stock Exchange
2.76
EUR
-0.04
- -
16.41MMarket Cap
Otofarma S.p.A.
OTO.MI
(Italian Stock Exchange)

Recent

price

2.76

P/E

ratio

- -

div

yld

- -

ROIC.AI

2023
2024
FRC
2.09
- -
Revenue per Share
0.09
- -
Basic EPS, GAAP
0.21
- -
Free Cash Flow per Basic Share
- -
- -
Dividend per Share
0.3
- -
Book Value per Share
0.39
- -
Tangible Book Value per Share
6
- -
Basic Weighted Avg Shares
12
15
Sales/Revenue/Turnover
8.94
12.73
Operating Margin (%)
- -
- -
Depreciation Expense
1
1
Net Income, GAAP
47.02
58.66
Effective Tax Rate (%)
4.2
4.59
Profit Margin (%)
2
4
Working Capital
1
1
LT Debt
3
5
Total Equity
- -
12.03
Return on Invested Capital (%)
- -
- -
Return on Capital (%)
- -
28.78
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
55.8%
Free Cash Flow
- -
- -
144.53%
Net Income, GAAP
- -
- -
37.94%
Sales/Revenue/Turnover
- -
- -
26.08%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
12
2024
- -
- -
- -
- -
15

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
0.09
2024
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
Similar Companies
Stryker Corporation (SYK.DE)
DVx Inc. (3079.T)
Siemens Healthineers AG (SEMHF)
Senzime AB (publ) (SEZI.ST)
Adagio Medical Holdings, Inc. (ADGM)
Tellgen Corporation (300642.SZ)
Business
Otofarma S.p.A. (OTO.MI) develops, manufactures, and commercializes innovative veterinary pharmaceutical products focused on animal ear health and dermatology. The company offers a range of specialized treatments including Otirex, a patented eardrop formulation for canine and feline otitis; Otodex, an advanced antimicrobial spray for ear infections; and complementary dermatological solutions such as anti-inflammatory shampoos and topical ointments under its proprietary brands, targeting veterinarians, pet clinics, and animal health distributors. Founded in 2018 and headquartered in Milan, Italy, Otofarma operates primarily in the European veterinary pharmaceuticals market, with distribution networks across Italy, Spain, France, and expanding into other EU countries. In late 2024, the company secured a strategic distribution partnership with a leading pan-European veterinary group to accelerate market penetration; additionally, it completed a €5 million Series B funding round in early 2025 led by Italian biotech investors, enabling the launch of a new line of probiotic-based ear care supplements and R&D expansion into feline-specific therapies.